Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients-Reference-Cited by-同舟云学术

Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

Published:2008-06-28 Issue:7 Volume:8 Page:1384-1392
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:

Author:

Kasiske B. L.,de Mattos A.,Flechner S. M.,Gallon L.,Meier-Kriesche H.-U.,Weir M. R.,Wilkinson A.

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2008.02272.x/fullpdf

Reference43 articles.

1. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease;Kidney Disease Outcomes Quality Initiative (K/DOQI) Group;Am J Kidney Dis,2003

2. Cardiovascular disease after renal transplantation;Kasiske;J Am Soc Nephrol,1996

3. Predicting coronary heart disease in renal transplant recipients: A prospective study;Ducloux;Kidney Int,2004

4. for Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine;Groth;Transplantation,1999

5. for Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study;Kahan;Lancet,2000

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carvacrol ameliorates skin allograft rejection through modulating macrophage polarization by activating the Wnt signalling pathway;Phytotherapy Research;2024-08-09

2. Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients;Kidney International;2024-07

3. Managing dyslipidemia in solid organ transplant patients;Indian Heart Journal;2024-03

4. mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation;Frontiers in Medicine;2023-05-12

5. Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus;Frontiers in Transplantation;2023-04-20